Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Invasive fungal infections contribute to the morbidity and mortality of immunosuppressed patients treated for hematologic malignancy and those undergoing hematopoietic cell transplantation. After years of limited advances, the management of fungal infections in these patients is now rapidly evolving. In this update, we will outline changes in the epidemiology of invasive fungal infections, discuss current issues in diagnosis and susceptibility testing, and review the current classes of antifungal drugs, focusing on newly licensed therapies. Data on antifungal prophylaxis, empiric therapy, and treatment of documented invasive fungal infections including single agents and combinations with newly licensed agents will be reviewed with emphasis on their impact on patients with hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)669-680
Number of pages12
JournalLeukemia and Lymphoma
Volume45
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Mycoses
Epidemiology
Hematologic Neoplasms
Cell Transplantation
Therapeutics
Morbidity
Mortality
Pharmaceutical Preparations
Invasive Fungal Infections

Keywords

  • Bone marrow transplantation
  • Leukemia lymphoma
  • Mycoses
  • Neutropenia
  • Opportunistic infection

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{ff364e4ca4d84bc29dcbfd8e7d9a661a,
title = "Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders",
abstract = "Invasive fungal infections contribute to the morbidity and mortality of immunosuppressed patients treated for hematologic malignancy and those undergoing hematopoietic cell transplantation. After years of limited advances, the management of fungal infections in these patients is now rapidly evolving. In this update, we will outline changes in the epidemiology of invasive fungal infections, discuss current issues in diagnosis and susceptibility testing, and review the current classes of antifungal drugs, focusing on newly licensed therapies. Data on antifungal prophylaxis, empiric therapy, and treatment of documented invasive fungal infections including single agents and combinations with newly licensed agents will be reviewed with emphasis on their impact on patients with hematologic malignancies.",
keywords = "Bone marrow transplantation, Leukemia lymphoma, Mycoses, Neutropenia, Opportunistic infection",
author = "Brandon Hayes-Lattin and Richard Maziarz",
year = "2004",
month = "4",
doi = "10.1080/10428190310001625719",
language = "English (US)",
volume = "45",
pages = "669--680",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders

AU - Hayes-Lattin, Brandon

AU - Maziarz, Richard

PY - 2004/4

Y1 - 2004/4

N2 - Invasive fungal infections contribute to the morbidity and mortality of immunosuppressed patients treated for hematologic malignancy and those undergoing hematopoietic cell transplantation. After years of limited advances, the management of fungal infections in these patients is now rapidly evolving. In this update, we will outline changes in the epidemiology of invasive fungal infections, discuss current issues in diagnosis and susceptibility testing, and review the current classes of antifungal drugs, focusing on newly licensed therapies. Data on antifungal prophylaxis, empiric therapy, and treatment of documented invasive fungal infections including single agents and combinations with newly licensed agents will be reviewed with emphasis on their impact on patients with hematologic malignancies.

AB - Invasive fungal infections contribute to the morbidity and mortality of immunosuppressed patients treated for hematologic malignancy and those undergoing hematopoietic cell transplantation. After years of limited advances, the management of fungal infections in these patients is now rapidly evolving. In this update, we will outline changes in the epidemiology of invasive fungal infections, discuss current issues in diagnosis and susceptibility testing, and review the current classes of antifungal drugs, focusing on newly licensed therapies. Data on antifungal prophylaxis, empiric therapy, and treatment of documented invasive fungal infections including single agents and combinations with newly licensed agents will be reviewed with emphasis on their impact on patients with hematologic malignancies.

KW - Bone marrow transplantation

KW - Leukemia lymphoma

KW - Mycoses

KW - Neutropenia

KW - Opportunistic infection

UR - http://www.scopus.com/inward/record.url?scp=1342344863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342344863&partnerID=8YFLogxK

U2 - 10.1080/10428190310001625719

DO - 10.1080/10428190310001625719

M3 - Article

C2 - 15160938

AN - SCOPUS:1342344863

VL - 45

SP - 669

EP - 680

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -